Overview
International law firm McDermott Will & Emery advised Apposite Capital, the healthcare specialist private equity investor, on its acquisition of a majority shareholding in CrestOptics, a world leader in the development and manufacture of advanced systems for fluorescence microscopy from XYence Capital SGR S.p.A. and management. As part of the transaction, the early-stage diagnostics research programmes that CrestOptic has been conducting with Istituto Italiano di Tecnologia (IIT) in the fields of cancer, Alzheimer’s disease and point of care virus detection have been spun off into a sister company, D-TAILS.
CrestOptics is a world leader in scientific optical instrumentation for Fluorescence Microscopy. It has been founded in 2009 by a team of people with a long and proven experience in scientific research, industrial design and manufacturing of electrooptical systems. The mission of the company is the production of state of art instruments using optical and electrooptical technology for scientific and industrial applications.
Apposite Capital is an independent investment firm focused exclusively on healthcare. It backs companies operating in health and social care, medtech & medical products, pharmaceuticals & life sciences and digital health.
McDermott’s cross-border team was led by counsel Calum Thom and included partner Fabrizio Faina, supported by associates Simona Siciliani, Stefano Pardini and trainee solicitor Lucio Caruso, in Milan.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
